Donna Elizabeth Hansel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Donna Elizabeth Hansel has a total of 348 co-authors. Here are the top co-authors by number of shared publications:
- Bin Tean Teh
Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore 169857, Singapore
11 shared publications - Alexandru Almasan
Department of Cancer Biology, Lerner Research Institute, Cleveland, USA
10 shared publications Jeffrey A. Ecsedy
9 shared publications- Maria Carmen Mir
Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, USA
9 shared publications Andrew M. Hau
DepartmentofPathology, UniversityofCalifornia, SanDiego, LaJolla, CA
8 shared publications- Daniel J. Lindner
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
8 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Methods file contains extended methods, including the processing and analysis of multiple sequencing datasets.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Methods file contains extended methods, including the processing and analysis of multiple sequencing datasets.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Tables file contains key information and supporting datasets. Table S1 | Clinicopathological features of the 22 MIBC patients. Table S2 | The top 50 most significantly differentially expressed genes between the 15 single cell clusters. Table S3 | GSEA pathway enrichment results for 4 spatial clusters. Table S4 | Clinical characteristics and spatial tumor state composition across samples. Table S5 | Bootstrap-based robustness analysis of spatial tumor state proportions. Table S6 | The top 50 most significantly differentially expressed genes between the 4 spatial clusters.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Tables file contains key information and supporting datasets. Table S1 | Clinicopathological features of the 22 MIBC patients. Table S2 | The top 50 most significantly differentially expressed genes between the 15 single cell clusters. Table S3 | GSEA pathway enrichment results for 4 spatial clusters. Table S4 | Clinical characteristics and spatial tumor state composition across samples. Table S5 | Bootstrap-based robustness analysis of spatial tumor state proportions. Table S6 | The top 50 most significantly differentially expressed genes between the 4 spatial clusters.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Figures file contains Supplementary Figures S1–S15. Figure S1 | Pathology-guided spatial annotation across 22 MIBC tumors. Figure S2 | Validation of spatial deconvolution accuracy and cell-type compartmentalization. Figure S3 | Additional tumors demonstrating spatial CNV-based subclones and transcriptional divergence. Figure S4 | Cross-platform concordance of CNV profiles inferred from spatial transcriptomics and WES. Figure S5 | Transcriptional and functional features across the luminal-to-basal differentiation continuum. Figure S6 | Single-cell analysis recapitulates the spatial luminal-to-basal differentiation continuum. Figure S7 | Spatial validation of lineage-associated EGFR and FGFR3 expression patterns. Figure S8 | Lineage-associated expression of FGFR3–EGFR signaling and transcriptional regulators across normal tissue, tumor states, and independent cohorts. Figure S9 | Pathology-guided spatial annotation across all MIBC tumors. Figure S10 | Spatial tumor states associate with chemotherapy response and stress-related gene expression. Figure S11 | NECTIN4 expression is enriched in luminal tumors and declines at the tumor-normal boundary. Figure S12 | Subtype-associated genomic alterations and their relationship with basal program activity. Figure S13 | Associations between basal signature scores and clinical or molecular features across MIBC cohorts. Figure S14 | Pathologist-guided TLS annotation confirms spatial transcriptomic predictions. Figure S15 | Lineage-associated chemokine programs and tumor–TLS interactions.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Figures file contains Supplementary Figures S1–S15. Figure S1 | Pathology-guided spatial annotation across 22 MIBC tumors. Figure S2 | Validation of spatial deconvolution accuracy and cell-type compartmentalization. Figure S3 | Additional tumors demonstrating spatial CNV-based subclones and transcriptional divergence. Figure S4 | Cross-platform concordance of CNV profiles inferred from spatial transcriptomics and WES. Figure S5 | Transcriptional and functional features across the luminal-to-basal differentiation continuum. Figure S6 | Single-cell analysis recapitulates the spatial luminal-to-basal differentiation continuum. Figure S7 | Spatial validation of lineage-associated EGFR and FGFR3 expression patterns. Figure S8 | Lineage-associated expression of FGFR3–EGFR signaling and transcriptional regulators across normal tissue, tumor states, and independent cohorts. Figure S9 | Pathology-guided spatial annotation across all MIBC tumors. Figure S10 | Spatial tumor states associate with chemotherapy response and stress-related gene expression. Figure S11 | NECTIN4 expression is enriched in luminal tumors and declines at the tumor-normal boundary. Figure S12 | Subtype-associated genomic alterations and their relationship with basal program activity. Figure S13 | Associations between basal signature scores and clinical or molecular features across MIBC cohorts. Figure S14 | Pathologist-guided TLS annotation confirms spatial transcriptomic predictions. Figure S15 | Lineage-associated chemokine programs and tumor–TLS interactions.
- Open Access
- 13 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 2037-2059
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. Here, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial–mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across over 3,000 tumors confirm conserved FGFR3–EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC.
- 13 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 2037-2059
Open AccessA Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. Here, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial–mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across over 3,000 tumors confirm conserved FGFR3–EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC.
- Open Access
- 18 January 2026
- Published by Elsevier in Human Pathology Reports
- Vol. 43
Pilomatrix-like high-grade carcinoma involving the urinary bladder: identification of APC mutation and potential for TROP-2 targeted therapy
- 18 January 2026
- Published by Elsevier in Human Pathology Reports
- Vol. 43
Open AccessPilomatrix-like high-grade carcinoma involving the urinary bladder: identification of APC mutation and potential for TROP-2 targeted therapy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 542 KB, Effects of combination treatments on membrane permeability. T24 cells subjected to combination treatments as described in Figure 5 were stained with trypan blue. Combination treatments resulted in an increased percentage of cells staining positive for trypan blue, most notably in the sequentially dosed combination regimens.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 542 KB, Effects of combination treatments on membrane permeability. T24 cells subjected to combination treatments as described in Figure 5 were stained with trypan blue. Combination treatments resulted in an increased percentage of cells staining positive for trypan blue, most notably in the sequentially dosed combination regimens.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 76 KB, Cell cycle analysis of MLN8237/paclitaxel and MLN8237/gemcitabine combination treatments. Propidium iodide staining with flow cytometry was performed to assess cell cycle changes. Simultaneous MLN8237/paclitaxel and MLN8237/gemcitabine treatments appeared to have little, if any, additional effect on cell cycle arrest compared to MLN8237 alone. Sequential treatments of MLN8237 followed by either paclitaxel or gemcitabine produced the greatest degree of cell cycle derangement.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 76 KB, Cell cycle analysis of MLN8237/paclitaxel and MLN8237/gemcitabine combination treatments. Propidium iodide staining with flow cytometry was performed to assess cell cycle changes. Simultaneous MLN8237/paclitaxel and MLN8237/gemcitabine treatments appeared to have little, if any, additional effect on cell cycle arrest compared to MLN8237 alone. Sequential treatments of MLN8237 followed by either paclitaxel or gemcitabine produced the greatest degree of cell cycle derangement.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 76 KB, Cell cycle analysis of MLN8237/paclitaxel and MLN8237/gemcitabine combination treatments. Propidium iodide staining with flow cytometry was performed to assess cell cycle changes. Simultaneous MLN8237/paclitaxel and MLN8237/gemcitabine treatments appeared to have little, if any, additional effect on cell cycle arrest compared to MLN8237 alone. Sequential treatments of MLN8237 followed by either paclitaxel or gemcitabine produced the greatest degree of cell cycle derangement.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
PDF file - 76 KB, Cell cycle analysis of MLN8237/paclitaxel and MLN8237/gemcitabine combination treatments. Propidium iodide staining with flow cytometry was performed to assess cell cycle changes. Simultaneous MLN8237/paclitaxel and MLN8237/gemcitabine treatments appeared to have little, if any, additional effect on cell cycle arrest compared to MLN8237 alone. Sequential treatments of MLN8237 followed by either paclitaxel or gemcitabine produced the greatest degree of cell cycle derangement.